Clinical trial
Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With…
NCT00320879 · Steno Diabetes Center Copenhagen, Other · Completed
Key facts
| NCT number | NCT00320879 |
|---|---|
| Title | Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria |
| Official title | Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria |
| Lead sponsor | Steno Diabetes Center Copenhagen, Other |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes, Microalbuminuria |
| Intervention type | Drug |
| Interventions | irbesartan |
| Enrollment | 52 |
| Start date | Sep 1, 2003 |
| Completion | Nov 1, 2004 |
| First posted | May 3, 2006 |
| Last update posted | May 18, 2006 |
| Countries | Denmark |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: